You are here:

Archived: fondaparinux (Arixtra)

Advice

Appropriate for use in NHS Scotland.

RECOMMENDATION

Compared with enoxaparin, fondaparinux has been shown to be associated with fewer thrombo-embolic events and a generally similar incidence of major bleeding. It is licensed for post-operative initiation, and this represents an advantage where regional anaesthesia and/or catheterisation are planned. It is predicted to be a cost effective alternative to enoxaparin in a robust economic model.

It may be considered for patients for whom antithrombotic therapy is appropriate, recognising that other antithrombotic agents and other approaches to prophylaxis may be more suitable in some situations.

Drug Details

Drug Name: fondaparinux (Arixtra)
SMC Drug ID: 18/02
Manufacturer: Sanofi-Aventis
Indication: Antithrombotic therapy
BNF Category:
Sub Category: 2.8 Anticoagulants and protamine
Submission Type: Full submission
Status: Accepted
Date Advice Published: 8 November 2002

Current Advice

Non submission 8 May 2006

Archived Advice

Non submission 8 May 2006

Back